This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Medshine Discovery Inc.. Active years: 2022-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2023
Title: Hailong Yang: Innovator in KRAS G12C Mutein Inhibitors
Introduction
Hailong Yang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical research, particularly in the development of KRAS G12C mutein inhibitors. With a total of two patents to his name, Yang is recognized for his innovative approach to drug discovery.
Latest Patents
Yang's latest patents include a class of pyridone-pyrimidine derivatives that act as KRAS G12C mutein inhibitors. These compounds are represented by a specific formula and include isomers and pharmaceutically acceptable salts. His work focuses on providing effective solutions for targeting KRAS G12C mutations, which are critical in various cancers.
Career Highlights
Hailong Yang is currently associated with Medshine Discovery Inc., where he continues to advance his research in the pharmaceutical sector. His expertise in medicinal chemistry and drug design has positioned him as a key player in the development of novel therapeutic agents.
Collaborations
Yang collaborates with notable colleagues, including Yaxian Cai and Zhaobing Xu, who contribute to his research endeavors. Their combined efforts enhance the innovation and effectiveness of the projects they undertake.
Conclusion
Hailong Yang's work in developing KRAS G12C mutein inhibitors showcases his dedication to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his innovative spirit continues to inspire future research in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile